Barely Significant
← all excerpts

Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.

Neurosurg Rev · 2026 · PMC13086805 · PMID 41989655

Europe PMCDOI
1
hedged sentence
0.0310
closest p · 0.6× alpha
0.0310
boldest claim

The sentences

nominally significantp = 0.031actually significant
A nominally significant difference was observed for bevacizumab at the 12-month landmark, favoring grade 2 over grade 3 (68.3% vs. 37.2%, p = 0.031); however, this isolated finding was not supported by a significant global log-rank comparison across grades ( p = 0.09) and was not consistently observed at other landmarks.

also in 4,457 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.